About
NRDL+ is a strategic intelligence platform focused on China’s evolving health policy, coverage, and financing system for medical technologies.
What began as independent policy commentary has evolved into a structured intelligence platform that helps life sciences leaders turn China’s policy, coverage, and financing complexity for medical technologies into clearer access strategies and better-informed commercial decisions.
NRDL+ connects system-level reform dynamics and implementation realities to real-world market access, portfolio, and commercialization decisions. We interpret policy signals, track shifts across coverage and funding pathways, and assess execution dynamics across basic medical insurance, commercial health insurance, and emerging access channels — clarifying their commercial and strategic implications for global life sciences leaders.
Our work is delivered through Access360, NRDL+’s membership program for ongoing China access intelligence, and NRDL+ Masterclass, an executive strategic foundation for China access decision-making.
NRDL+ Executive Debrief is powered by bizi LLC, a New Jersey–based consultancy with over a decade of experience advising life sciences leadership teams on pricing, reimbursement, and market access across global and local markets..
People
Kelly Ke
Founder, bizi LLC | Architect of NRDL+
Kelly Ke is the founder of bizi LLC and the architect of NRDL+, a strategic intelligence platform focused on China’s evolving health policy, coverage, and financing system.
Prior to founding bizi LLC, Kelly spent a decade as an award-winning senior advisor in Deloitte US’s Life Sciences practice. Since then, she has led bizi’s work advising global life sciences leadership teams on pricing, reimbursement, and market access strategy across global and local market contexts.
Operating at the intersection of health policy and strategic decision-making, Kelly provides structured interpretation of policy signals within China’s evolving coverage and financing system — helping life sciences leaders connect system-level developments to pricing assumptions, reimbursement strategy, utilization, and broader access and go-to-market planning.
Her co-authored policy analysis has been published in Caixin and subsequently republished in China Reform magazine, contributing to industry dialogue on China’s evolving multi-layer coverage framework. Her work is followed by executives across more than two-thirds of the world’s top 30 pharmaceutical companies, as well as leaders from biotechs, insurers, hospital groups, and academic institutions.
Kelly collaborates with a curated network of leading China policy and industry experts, integrating field-grounded insight on policy design and implementation into the NRDL+ intelligence framework.
Originally from Beijing, Kelly holds master’s degrees from the University of Southern California and the University of Utah, and a postgraduate certificate in International Health Technology Assessment (HTA) and Reimbursement from the University of Sheffield.